Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $17.9 million.

  • Entrada Therapeutics' Share-based Compensation rose 5.27% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 16.97%. This contributed to the annual value of $17.9 million for FY2024, which is 36.64% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Share-based Compensation is $17.9 million, which was up 36.64% from $13.1 million recorded in FY2023.
  • Entrada Therapeutics' Share-based Compensation's 5-year high stood at $17.9 million during FY2024, with a 5-year trough of $325,000 in FY2020.
  • Its 3-year average for Share-based Compensation is $13.6 million, with a median of $13.1 million in 2023.
  • Data for Entrada Therapeutics' Share-based Compensation shows a peak YoY spiked of 677.23% (in 2021) over the last 5 years.
  • Entrada Therapeutics' Share-based Compensation (Yearly) stood at $325,000 in 2020, then surged by 677.23% to $2.5 million in 2021, then surged by 291.73% to $9.9 million in 2022, then surged by 32.50% to $13.1 million in 2023, then skyrocketed by 36.64% to $17.9 million in 2024.